Opioid analgesic with abuse-deterrent formulation

This page covers all Opioid analgesic with abuse-deterrent formulation drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism), Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonist).

Targets

Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism) · Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonist)

Marketed (3)

• oxycodone naloxone tablet · Mundipharma Research GmbH & Co KG · Pain Management
  Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is an opioid antagonist included to reduce abuse potential by blocking euphoric effects if the tablet is tampered with.
• Prolonged-release oxycodone/naloxone · Kati Järvelä · Pain Management
  Oxycodone acts as a mu-opioid receptor agonist for pain relief, while naloxone is an opioid antagonist included to reduce abuse potential by blocking euphoric effects if the formulation is tampered with.
• Oxycodone/Naloxone Prolonged Release · Grünenthal GmbH · Pain Management
  Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed and injected.

Phase 3 pipeline (2)

• Oxycodone/Naloxone Prolonged Release tablets · Mundipharma Research GmbH & Co KG · Pain Management
  Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed or dissolved.
• Oxycodone/Naloxone controlled-release · Purdue Pharma LP · Pain Management
  Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential.